Posted by Michael Wonder on 02 Feb 2022
FDA approves first generic of Restasis
2 February 2022 - The U.S. FDA has approved the first generic of Restasis (cyclosporin ophthalmic emulsion) 0.05% single use vials (eye drops) to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca (commonly known as dry eye).
The sponsor of the generic cyclosporin ophthalmic emulsion 0.05% single-use vials approved today is Mylan.
